MCL1 and Miyoshi myopathy: In conclusion, these findings show that KS18 is an excellent Mcl-1 inhibitor, offering promise as an adjuvant therapy in combination with various agents including bortezomib, cyclophosphamide, doxorubicin, venetoclax against a spectrum of resistant MM cells.